“Background: The histamine receptors have therapeutic rele


“Background: The histamine receptors have therapeutic relevance in treatment of several diseases with the more recently discovered H-3 and H-4 receptors offering opportunity as new therapeutic drug targets. Thus, it is of interest to develop

new, potent and therapeutically relevant drugs with no side effects. Molecular modeling techniques may play an important role in quickly designing new ligands with a likelihood of exhibiting the corresponding pharmacological profile. Objective: The article describes the findings obtained from this approach for all of the histamine receptors with special emphasis on the H-3 and H-4 receptors. Conclusion: There have been several new studies in the past years aimed at

developing new histamine receptor ligands on the one hand and at explaining GM6001 in vitro pharmacological profiles on molecular level on the other. For these purposes, not only molecular modeling GSK923295 purchase techniques, but also synthesis, pharmacological characterization, molecular biological and physical techniques are useful. This combination of several different theoretical and experimental techniques allows getting a more detailed insight into the interaction of histamine receptor ligands with histamine receptors and developing new drugs.”
“Background The alpha 7 subunit of nicotinic acetylcholine receptors (alpha 7nAChR) can negatively regulate the synthesis and release of proinflammatory cytokines by macrophages and fibroblast-like synoviocytes in vitro. In addition, stimulation of the alpha 7nAChR can reduce the P5091 mw severity of arthritis in murine collagen-induced arthritis (CIA).\n\nObjective To provide more insight into the role of the alpha 7nAChR in the pathogenesis of arthritis

by investigating the effect of the absence of alpha 7nAChR in CIA in alpha 7-deficient (alpha 7nAChR(-/-)) compared with wild-type (WT) mice.\n\nMethods CIA was induced in alpha 7nAChR(-/-) and WT littermate mice at day 0 by immunisation with chicken collagen type II (cCII) followed by a booster injection with cCII on day 20. Mice were killed on day 44 or day 63 and arthritis activity as well as radiological and histological damage were scored. The effects on the immune response were evaluated by measurement of antigen-specific antibodies and cytokines, and evaluation of the effects on antigen-specific stimulated spleen cells.\n\nResults In alpha 7nAChR(-/-) mice a significant increase in the incidence and severity of arthritis as well as increased synovial inflammation and joint destruction were seen. Exacerbation of CIA was associated with elevated systemic proinflammatory cytokines and enhanced T-helper cell 1 (Th1)-cytokine and tumour necrosis factor alpha production by spleen cells. Moreover, a specific decrease in the collagen-specific ‘Th1-associated’ IgG2a response was seen, whereas IgG1 titres were unaffected.

Comments are closed.